Regorafenib for metastatic colorectal cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hyun, Myung Han | - |
dc.contributor.author | Shin, Mi Ran | - |
dc.contributor.author | Kim, Yeul Hong | - |
dc.date.accessioned | 2021-09-06T01:40:15Z | - |
dc.date.available | 2021-09-06T01:40:15Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2013-05-04 | - |
dc.identifier.issn | 0140-6736 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/103251 | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER SCIENCE INC | - |
dc.subject | MUTATIONS | - |
dc.subject | CETUXIMAB | - |
dc.title | Regorafenib for metastatic colorectal cancer | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Yeul Hong | - |
dc.identifier.doi | 10.1016/S0140-6736(13)60977-0 | - |
dc.identifier.scopusid | 2-s2.0-84877291709 | - |
dc.identifier.wosid | 000318609600022 | - |
dc.identifier.bibliographicCitation | LANCET, v.381, no.9877, pp.1537 - 1538 | - |
dc.relation.isPartOf | LANCET | - |
dc.citation.title | LANCET | - |
dc.citation.volume | 381 | - |
dc.citation.number | 9877 | - |
dc.citation.startPage | 1537 | - |
dc.citation.endPage | 1538 | - |
dc.type.rims | ART | - |
dc.type.docType | Letter | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordPlus | MUTATIONS | - |
dc.subject.keywordPlus | CETUXIMAB | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.